XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma.

Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Refractory Multiple Myeloma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

ONC-206 is under clinical development by Chimerix and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.

TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).